scholarly journals Takayasu arteritis

2021 ◽  
pp. 5-14
Author(s):  
N.V. Bortnyak ◽  
◽  
O.A. Yepanchintseva ◽  
A.V. Khokhlov ◽  
B.M. Todurov ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Surgical Treatment ◽  
Disease Activity ◽  
Takayasu Arteritis ◽  
Clinical Course ◽  
Close Attention ◽  
Rare Form ◽  
Treatment Methods ◽  
Large Arteries ◽  
Low Prevalence

Takayasu arteritis is a rare form of the vasculitis of large arteries. It is a disease difficult to diagnose and treat, often unpredictable in terms of outcome and life-treatening. Despite its low prevalence, Takayasu arteritis deserves close attention for therapists, cardiologists, rheumatologists and angiosurgeons. This article presents classifications, features of the clinical course of the disease, possibilities of the visualization diagnosis of the lesions of arteries, assessment of the disease activity. The issues of the contemporary drug therapy, interventional and surgical treatment methods and complications of the disease are presented.

scholarly journals A rare case of mechanical conjunctivitis

2018 ◽  
Vol 11 (3) ◽  
pp. 74-77
Author(s):  
Inna A. Riks ◽  
Sanasar S. Papayan ◽  
Pavel A. Nechiporenko
Keyword(s):  
Surgical Treatment ◽  
Rare Case ◽  
Correct Diagnosis ◽  
Diagnosis And Treatment ◽  
Inflammatory Condition ◽  
Rare Form ◽  
Rare Type ◽  
Treatment Methods ◽  
Long Period

Introduction. Mechanical conjunctivitis is a rare form of eye surface inflammatory condition. One of its types, a mucus fishing syndrome, leads to a chronic eye surface trauma. Purpose. To review the available literature data on the mechanical conjunctivitis prevalence, and to describe the diagnosis and treatment methods of its rare type, the mucus fishing syndrome. Materials and methods. The article describes the case of the mucus fishing syndrome development in a patient suffering from this type of mechanical conjunctivitis for about 3 years. Results. The correct diagnosis was not established in our patient for a long period of time that is why an improper treatment had been prescribed, which led to complications and to the need for surgical treatment. Conclusions. The prevalence of mechanical conjunctivitis is low, and in the available literature, there are only 4 publications on the topic. The mucus fishing syndrome should be treated in cooperation with a psychiatrist, since the usual use of topical reparative and lubricating therapy is not enough.

scholarly journals TAKAYASU ARTERITIS: A REVIEW

2013 ◽  
Vol 19 (6) ◽  
pp. 478-476
Author(s):  
N. S. Goncharova ◽  
M. V. Samokhvalova ◽  
A. V. Pakhomov ◽  
D. A. Zverev ◽  
O. M. Moiseeva
Keyword(s):  
Surgical Treatment ◽  
Takayasu Arteritis ◽  
Serum Biomarkers ◽  
Current Evidence ◽  
Evidence Based ◽  
Rare Form ◽  
Imaging Diagnostics ◽  
Activity Assessment ◽  
Evidence Based Treatments ◽  
Disease Activity Assessment

Takayasu arteritis is a well-known rare form of large vessel vasculitis. This review details the clinical features, opportunities of disease activity assessment including new serum biomarkers and imaging diagnostics. Current evidence based treatments are presented and discussed. Particular attention is paid to the effectiveness and complications of interventional and surgical treatment in arteritis Takayasu.

The rationale for the combined use of osteopathic methods of correction and reflexology in the complex treatment of patients with dorsopathy at the cervico-thoracic level

2020 ◽  
pp. 82-94 ◽  
Author(s):  
V. O. Belash ◽  
L. R. Urazgalieva ◽  
R. I. Fayzullina ◽  
L. G. Agasarov
Keyword(s):  
Drug Therapy ◽  
Drug Treatment ◽  
Pain Syndrome ◽  
Clinical Effectiveness ◽  
Complex Treatment ◽  
Standard Drug ◽  
Treatment Methods ◽  
Thoracic Level ◽  
Combined Use ◽  
Complex Therapy

Introduction. Degenerative-dystrophic changes in the spine are the most common chronic human diseases. Pronounced clinical manifestations of vertebrogenic diseases are observed during active labor activity and represent one of the most frequent causes of temporary disability. It is also known that any pain syndromes are accompanied by the development of psychovegetative disorders, which reduces the effectiveness of treatment. In recent years, there has been a reasonable increase in the interest of the medical community to the non-drug treatment methods. It is caused by the polypharmacotherapy side effects, an increased numbers of allergic reactions, problems with polypragmasia, and a low level of compliance. At the same time, the question of the possibility of various non-drug treatment methods combining is quite acute.The goal of research is to substantiate the clinical effectiveness of the combined application of osteopathic correction and reflexotherapy in the complex treatment of patients with dorsopathy at the cervical-thoracic level.Materials and methods. A prospective controlled randomized study was conducted on the basis of the medical clinics of LLC «Family Health» (Kazan) and ANO «Center for SEB assistance» (Kazan) from April 2018 to May 2019. The study involved 52 people with dorsopathy at the cervical-thoracic level, aged from 25 to 45 years. In accordance with the exclusion criteria, 7 people dropped out of the study. The remaining patients (45 people), depending on the used treatment method, were divided by a simple randomization method using a random number generator into three groups of 15 people. The first group (main group) received osteopathic correction and reflexotherapyon the background of standard drug therapy; the second and the third groups (control groups) received only osteopathic correction orreflexotherapy, respectively, on the background of standard drug therapy. The osteopathic examination was performed for all patients regardless of the group, before and after the course of therapy, with the formation of an osteopathic conclusion.Also there was the estimation of the degree of pain syndrome severity,the asthenia, and the degree of accumulated emotional and energy charge that does not get out in a person.Results. It was found in the course of the study that the inclusion of osteopathic correction and reflexotherapy in the complex therapy of patients with dorsopathy at the cervical-thoracic level is clinically more effective than the isolated use of these methods. Such complex therapy allows to achieve a more significant reduction in the severity of the pain syndrome by VAS (p<0,05), relief of internal emotional tension (p<0,05), and increase the effectiveness of correction of dominant somatic dysfunction. Based on the obtained data, it could be assumed that reflexotherapy potentiates the effects of osteopathic correction.Conclusion. Based on the study, it can be concluded that the combination of osteopathic correction and reflexotherapy in the treatment of patients with dorsopathy at the cervical-thoracic level increases the clinical effectiveness of the standard drug therapy. At the same time, it is worth noting the potentiating effect of the combined use of two non-medicinal methods. The question of combining of various non-drug treatment methods is quite acute today, so this study will be continued. 

Case of follow-up and successful surgical treatment rare form of subaortic membrane in infant

2017 ◽  
Vol 14 (3) ◽  
pp. 161-165
Author(s):  
A.I. Kim ◽  
Т.V. Rogova ◽  
R.М. Кurganov ◽  
Е.V. Kholmanskaya
Keyword(s):  
Surgical Treatment ◽  
Rare Form ◽  
Subaortic Membrane

scholarly journals AB0509 SUSPENSIVE EFFICACY OF TOCILIZUMAB IN TREATMENT-NAÏVE PATIENTS WITH TAKAYASU ARTERITIS: TOCITAKA FRENCH PROSPECTIVE MULTICENTER OPEN-LABELLED TRIAL.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1552.3-1552
Author(s):  
A. Mekinian ◽  
D. Saadoun ◽  
J. C. N. F. [email protected] ◽  
I. Q. M. F. [email protected] ◽  
P. Jégo ◽  
...  
Keyword(s):  
Disease Activity ◽  
Takayasu Arteritis ◽  
Immunosuppressive Drugs ◽  
Relapse Free Survival ◽  
Research Support ◽  
Free Survival ◽  
Treatment Naïve ◽  
Steroid Sparing

Objectives:To assess long term efficacy of tocilizumab in treatment-naive patients with Takayasu arteritis (TAK).Methods:In this multicenter, prospective, open-labelled trial, we aim to evaluate the benefit of adding tocilizumab to steroids in treatment-naïve patients with TAK, on discontinuation of steroids after 6 months of tocilizumab treatment, and to assess relapse-free survival following tocilizumab discontinuation.Results:Thirteen patients with TAK were included, with a median age of 32 years [19-45] and 12 (92%) females. Six (54%) patients met the primary end-point. Among 11 (85%) patients which achieved remission at 6 months, 6 (54%) have reached primary endpoint.. Among the 5 remaining patients which continued steroids, 3 had a prednisone-equivalent dosage < 5mg/day. A significant decrease of disease activity was observed after 6 months of tocilizumab therapy: decrease of median NIH scale (3 [3-4] at baseline, versus 1 [0-2] after 6 months; p <0.001), ITAS-2010 score (5 [2-7] versus 3 [0-8]; p = 0.002), and ITAS-A score (7 [4-10] versus 4 [1-15]; p = 0.0001)]. All patients discontinued tocilizumab after 7 infusions, and no other immunosuppressive drugs was introduced, except for 1 patient which received methotrexate. After 9 and 12 months, respectively 7 (54%) and 6 (50%) patients achieved remission with less than 7.5 mg/day of prednisone, and 9 (69%) and 9 (75%) with doses <10 mg/day. During the 12 months follow-up after tocilizumab discontinuation, a relapse occurred among 5 patients (45%) out of 11 in which achieved remission after 6 months of tocilizumab.No severe AEs were considered related to study treatment and none required tocilizumab interruption or dose reduction. No deaths have occurred during the study period.Conclusion:Tocilizumab seems an effective steroid sparing therapy in TAK but its effect appears to be suspensive.Disclosure of Interests:Arsene Mekinian: None declared, david Saadoun: None declared, [email protected] [email protected]: None declared, [email protected] [email protected]: None declared, Patrick Jégo: None declared, [email protected] [email protected]: None declared, wxv wxv: None declared, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, Mathieu Vautier: None declared, [email protected]>; [email protected]>;: None declared, Patrice cacoub: None declared, olivier fain: None declared

scholarly journals AB0571 IS RITUXIMAB AN ADEQUATE GLUCOCORTICOID SPARING AGENT IN IDIOPATHIC INFLAMMATORY MYOPATHIES?

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1582.1-1582
Author(s):  
B. H. Egeli ◽  
S. Ergun ◽  
Y. K. Gursoy ◽  
A. Cetin ◽  
S. Ugurlu
Keyword(s):  
Disease Activity ◽  
Alternative Treatment ◽  
Statistical Power ◽  
Signs And Symptoms ◽  
Small Sample ◽  
Idiopathic Inflammatory Myopathies ◽  
Inflammatory Myopathies ◽  
Treatment Methods ◽  
Before And After

Background:Idiopathic inflammatory myopathies (IIM) are essentially treated aiming improvement of muscle function and extra muscular disease manifestations. The backbone of the treatment is corticosteroids enhancing the survival and patient quality of life. The lack of consensus on target-specific immunosuppressive treatment highlights the need for further studies evaluating alternative treatment methods. Rituximab is potentially a glucocorticoid-sparing agent which was reviewed in multiple studies with small sample sizes due to the rarity of the disease.Objectives:Higher statistical power can enhance the trustworthiness of alternative treatment methods yielding the main objective of this study.Methods:This retrospective study was conducted at a tertiary rheumatology center. Patients were diagnosed with an idiopathic inflammatory myopathy (dermatomyositis [DM], polymyositis [PM]) and were treated with rituximab in order to be included in this study. Clinical signs and symptoms of the presentation were noted during the first patient encounter as well as the follow-up. Parameters of disease activity including acute phase reactants, muscle enzyme levels, and disease-specific autoantibodies were analyzed.Results:The study includes 28 patients (20 DM, 8 PM). The age of diagnosis was 43.44 ± 15.77 years, follow-up duration was 60.7 ± 70.7 months. The presenting signs and symptoms of the patients are shown in Figure 1. The parameters of disease activity before and after treatment are summarized in Table 1. The mean corticosteroid dose decreased from 31.429 ±23.934 mg to 10.278 ±12.001 (p=0.001). Other treatment methods were methotrexate (n=18), Intravenous Immunoglobulin (IVIG) (n=7), and cyclophosphamide (n=2). There were not any deaths during the follow-up. Two patients were lost to follow-up.Table 1.The Parameters of Disease Activity Before and After TreatmentBefore TreatmentAfter TreatmentP ValueCPK, mean ± std (U/L)1426 ± 2049.92263.44 ± 265.630.004LDH, mean ± std (U/L)557.5 ± 365379.78 ± 192.10.03AST, mean ± std (U/L)62.52 ± 5930.16 ± 27.590.01ALT, mean ± std (U/L)56.48 ± 49.2127.64 ± 24.520.008ESR, mean ± std (mm/hour)26.38 ± 28.9820.39 ± 18.760.36CRP, mean ± std (mg/L)19.23 ± 46.1512.53 ± 26.670.5RF, mean ± std (U/mL)0 (0)N/AN/AANA, n (%)3 (10.71)N/AN/AFigure 1.The Presenting Signs and Symptoms of the PatientsConclusion:Rituximab is shown to be effective in treating myositis along with corticosteroids as well as a corticosteroid-sparing agent in retrospective studies and open-label clinical trials; however, lack of statistical power should be underlined. Long term decrease in steroid use and decrease in disease activity markers hints the effective use of rituximab as a glucocorticoid sparing agent as well as its safety with minimal side effects.Disclosure of Interests:None declared

scholarly journals Serum C1q concentration is associated with disease activity in Chinese Takayasu arteritis patients: A case‐control study

2021 ◽  
Vol 4 (2) ◽  
Author(s):  
Si Chen ◽  
Haixia Luan ◽  
Jianxun He ◽  
Yan Wang ◽  
Xiaoli Zeng ◽  
...  
Keyword(s):  
Disease Activity ◽  
Takayasu Arteritis ◽  
Case Control Study ◽  
Case Control ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document